Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Ortiz-Morales MJ"'
Autor:
Ortiz-Morales MJ; Medical Oncology Department, Reina Sofía University Hospital, 14004 Córdoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Córdoba, Spain.; Department of Medicine, Faculty of Medicine, University of Córdoba, 14004 Córdoba, Spain., Toledano-Fonseca M; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Córdoba, Spain.; Cancer Network Biomedical Research Centre (CIBERONC), 28029 Madrid, Spain., Mena-Osuna R; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Córdoba, Spain.; Cancer Network Biomedical Research Centre (CIBERONC), 28029 Madrid, Spain., Cano MT; Medical Oncology Department, Reina Sofía University Hospital, 14004 Córdoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Córdoba, Spain., Gómez-España A; Medical Oncology Department, Reina Sofía University Hospital, 14004 Córdoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Córdoba, Spain.; Department of Medicine, Faculty of Medicine, University of Córdoba, 14004 Córdoba, Spain., Haba-Rodríguez JR; Medical Oncology Department, Reina Sofía University Hospital, 14004 Córdoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Córdoba, Spain.; Department of Medicine, Faculty of Medicine, University of Córdoba, 14004 Córdoba, Spain.; Cancer Network Biomedical Research Centre (CIBERONC), 28029 Madrid, Spain., Rodríguez-Ariza A; Medical Oncology Department, Reina Sofía University Hospital, 14004 Córdoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Córdoba, Spain.; Cancer Network Biomedical Research Centre (CIBERONC), 28029 Madrid, Spain., Aranda E; Medical Oncology Department, Reina Sofía University Hospital, 14004 Córdoba, Spain.; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Córdoba, Spain.; Department of Medicine, Faculty of Medicine, University of Córdoba, 14004 Córdoba, Spain.; Cancer Network Biomedical Research Centre (CIBERONC), 28029 Madrid, Spain.
Publikováno v:
Cancers [Cancers (Basel)] 2022 Jun 21; Vol. 14 (13). Date of Electronic Publication: 2022 Jun 21.
Autor:
Élez E; Department of Medical Oncology, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, 119, 08035, Barcelona, Spain., Gómez-España MA; Department of Medical Oncology, IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Avenida Menéndez Pidal, S/N, 14004, Córdoba, Spain., Grávalos C; Department of Medical Oncology, H. Universitario 12 de Octubre, Instituto de Investigación i + 12, Avenida de Córdoba, S/N, 28041, Madrid, Spain., García-Alfonso P; Department of Medical Oncology, H. Gregorio Marañón, Calle del Doctor Esquerdo, 46, 28007, Madrid, Spain., Ortiz-Morales MJ; Department of Medical Oncology, IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Avenida Menéndez Pidal, S/N, 14004, Córdoba, Spain., Losa F; Department of Medical Oncology, H. Sant Joan Despí - Moisés Broggi, Carrer d'Oriol Martorell, 12, 08970, Sant Joan Despí, Barcelona, Spain., Díaz IA; Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica. Hospitales Universitarios Regional y Virgen de la Victoria. IBIMA, Campus de Teatinos, S/N, 29010, Málaga, Spain., Graña B; Department of Medical Oncology, C. H. Universitario, Lugar, Xubias de Arriba, 84, 15006, A Coruña, Spain., Toledano-Fonseca M; Department of Medical Oncology, IMIBIC, Reina Sofía Hospital, CIBERONC, Instituto de Salud Carlos III, Avenida Menéndez Pidal, S/N, 14004, Córdoba, Spain., Valladares-Ayerbes M; Department of Medical Oncology, H. Virgen del Rocío, IBIS, Av. Manuel Siurot s/n, 41013, Sevilla, Spain., Polo E; Department of Medical Oncology, H. Miguel Servet, Paseo Isabel la Católica, 1-3, 50009, Zaragoza, Spain., Salgado M; Department of Medical Oncology, C. H. Universitario de Ourense, Calle Ramón Puga Noguerol, 54, 32005, Orense, Spain., Martínez de Castro E; Department of Medical Oncology, H. Universitario Marqués de Valdecilla, IDIVAL, Avenida de Valdecilla, 25, 39008, Santander, Spain., Safont MJ; Department of Medical Oncology, H. General Universitario, CIBERONC, Avenida de les Tres Creus, 2, 46014, Valencia, Spain., Salud A; Department of Medical Oncology, H. de Lleida Arnau de Vilanova, Avenida Alcalde Rovira Roure, 80, 25198, Lérida, Spain., Ruiz-Casado A; Department of Medical Oncology, H. Puerta de Hierro Majadahonda, Calle Joaquín Rodrigo, 1, 28222, Majadahonda, Spain., Tabernero J; Department of Medical Oncology, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Passeig de la Vall d'Hebron, 119, 08035, Barcelona, Spain., Riesco MDC; Department of Medical Oncology, H. Universitario 12 de Octubre, Instituto de Investigación i + 12, Avenida de Córdoba, S/N, 28041, Madrid, Spain., Rodriguez-Ariza A; Department of Medical Oncology, IMIBIC, Reina Sofía Hospital, CIBERONC, Instituto de Salud Carlos III, Avenida Menéndez Pidal, S/N, 14004, Córdoba, Spain., Aranda E; Department of Medical Oncology, IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III, Avenida Menéndez Pidal, S/N, 14004, Córdoba, Spain. earandaa@seom.org.
Publikováno v:
British journal of cancer [Br J Cancer] 2022 Apr; Vol. 126 (6), pp. 874-880. Date of Electronic Publication: 2021 Dec 22.
Autor:
García-Alfonso P; Servicio de Oncología, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain. pgarcaalfonso@gmail.com., Díaz-Rubio E; CIBERONC, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clinico San Carlos (IdISSC), Madrid, Spain., Abad A; ICO, Hospital Germans Trias i Pujol, Badalona, Spain.; IOR Hospital Universitario Dexeus, Barcelona, Spain., Carrato A; IRYCIS, CIBERONC, Hospital Universitario Ramón y Cajal, Alcalá University, Madrid, Spain., Massutí B; Hospital General Universitario de Alicante, Alicante, Spain., Ortiz-Morales MJ; IMIBIC, CIBERONC, Reina Sofía Hospital, Instituto de Salud Carlos III, University of Córdoba, Córdoba, Spain., Manzano Mozo JL; ICO, Hospital Germans Trias i Pujol, Badalona, Spain., Muñoz A; Servicio de Oncología, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Durán G; Hospital Universitario Regional y Virgen de la Victoria, Malaga, Spain., Sastre J; CIBERONC, Hospital Clínico San Carlos, Instituto de Investigación Hospital Clinico San Carlos (IdISSC), Madrid, Spain., Safont MJ; Hospital General Universitario de Valencia, Valencia, Spain., Ferreiro R; IRYCIS, CIBERONC, Hospital Universitario Ramón y Cajal, Alcalá University, Madrid, Spain., Rivera F; Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain., González E; Hospital Virgen de las Nieves, Granada, Spain., Valladares-Ayerbes M; Instituto de Investigación Biomédica (INIBIC), Complejo Hospitalario Universitario A Coruña, A Coruña, Spain., Grávalos C; Hospital Universitario, 12 de Octubre, Madrid, Spain., Alonso-Orduña V; Instituto de Investigación Sanitaria de Aragón (IISA), Hospital Universitario Miguel Servet, Zaragoza, Spain., Viéitez JM; Hospital Universitario Central de Asturias, Oviedo, Spain., Yubero A; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain., Aranda E; IMIBIC, CIBERONC, Reina Sofía Hospital, Instituto de Salud Carlos III, University of Córdoba, Córdoba, Spain.
Publikováno v:
Drugs & aging [Drugs Aging] 2021 Mar; Vol. 38 (3), pp. 219-231. Date of Electronic Publication: 2021 Feb 22.
Autor:
Sastre J; Medical Oncology Hospital Clínico San Carlos, University Complutense Instituto de investigación Hospital Clínico San Carlos (IdISCC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Electronic address: jsastrev@salud.madrid.org., Orden V; CTC Unit, Molecular Oncology Laboratory, Hospital Clínico San Carlos, Instituto de investigación Hospital Clínico San Carlos (IdISCC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Martínez A; Laboratory, H. Universitario Reina Sofía, Córdoba, Spain., Bando I; Laboratory, Hospital Clínico San Carlos, Instituto de investigación Hospital Clínico San Carlos (IdISCC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Balbín M; Molecular Oncology Laboratory, H. Universitario Central de Asturias, Oviedo, Spain., Bellosillo B; Molecular Biology Laboratory, Hospital del Mar, Barcelona, Spain., Palanca S; Molecular Biology Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain., Peligros Gomez MI; Pathology Department, H. Gregorio Marañón, Madrid, Spain., Mediero B; CTC Unit, Molecular Oncology Laboratory, Hospital Clínico San Carlos, Instituto de investigación Hospital Clínico San Carlos (IdISCC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Llovet P; Laboratory, Hospital Clínico San Carlos, Instituto de investigación Hospital Clínico San Carlos (IdISCC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Moral VM; Laboratory, H. Universitario Reina Sofía, Córdoba, Spain., Viéitez JM; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain., García-Alfonso P; Medical Oncology Department, Hospital Gregorio Marañón, Madrid, Spain., Calle SG; Medical Oncology Department, Hospital Regional Universitario, Málaga, Spain., Ortiz-Morales MJ; Medical Oncology IMIBIC, Reina Sofía Hospital, University of Córdoba, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III, Córdoba, Spain., Salud A; Medical Oncology Department, Hospital de Lleida Arnau de Vilanova, Lérida, Spain., Quintero G; Medical Oncology Department, Hospital Lucus Augusti, Lugo, Spain., Lopez C; Medical Oncology Department, Hospital Marqués de Valdecilla, Santander, Spain., Díaz-Rubio E; Medical Oncology Hospital Clínico San Carlos, University Complutense Instituto de investigación Hospital Clínico San Carlos (IdISCC), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Aranda E; Medical Oncology IMIBIC, Reina Sofía Hospital, University of Córdoba, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Instituto de Salud Carlos III, Córdoba, Spain.
Publikováno v:
Clinical colorectal cancer [Clin Colorectal Cancer] 2020 Sep; Vol. 19 (3), pp. e110-e116. Date of Electronic Publication: 2020 Mar 06.
Autor:
García-Donas J; HM Hospitales, Centro Integral Oncológico HM Clara Campal, Madrid, Spain. Electronic address: jgarciadonas@gmail.com., Leon LA; Axencia de Coñocemento en Saúde (ACIS). SERGAS. Santiago de Compostella, Spain., Esteban E; Hospital Universitario Central de Asturias, Oviedo Asturias, Spain., Vidal-Mendez MJ; Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofia Hospital University of Cordoba, Spain., Arranz JA; Hospital Universitario Gregorio Marañón, Madrid, Spain., Garcia Del Muro X; Instituto Catalán de Oncología Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain., Basterretxea L; Hospital Universitario Donostia, Begiristain Doktorea Pasealekua, Donostia, Gipuzkoa, Spain., González Del Alba A; Hospital Universitario Son Espases, Palma de Mallorca, Spain., Climent MA; Fundacion Instituto Valenciano de Oncologia, Valencia, Spain., Virizuela JA; Hospital Universitario Virgen Macarena, Sevilla, Spain., Álvarez C; Hospital Universitario Central de Asturias, Oviedo Asturias, Spain., Sepúlveda J; Hospital Universitario Doce de Octubre, Madrid, Spain., Anido U; Complejo Hospitalario Universidad de Santiago, Santiago de Compostela, Spain., López C; Hospital Universitario Gregorio Marañón, Madrid, Spain., Ortiz-Morales MJ; Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofia Hospital University of Cordoba, Spain., Pérez X; Clinical Trial Unit, Catalan Institute of Oncology (IDIBELL), l'Hospitalet de Llobregat, Spain., Rodriguez-Antona C; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain., Rodriguez-Moreno JF; HM Hospitales, Centro Integral Oncológico HM Clara Campal, Madrid, Spain., Hernando S; Hospital Universitario Fundacion Alcorcon, Alcorcón, Madrid, Spain., Castellano D; Complejo Hospitalario Universidad de Santiago, Santiago de Compostela, Spain.
Publikováno v:
European urology focus [Eur Urol Focus] 2017 Oct; Vol. 3 (4-5), pp. 430-436. Date of Electronic Publication: 2016 Oct 04.
KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors.
Autor:
Morales-Estevez C; Medical Oncology Department, IMIBIC, Reina Sofia University Hospital, University of Cordoba , Cordoba , Spain., De la Haba-Rodriguez J; Medical Oncology Department, IMIBIC, Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Madrid, Spain., Manzanares-Martin B; Immunology Department, IMIBIC, Reina Sofia University Hospital, University of Cordoba , Cordoba , Spain., Porras-Quintela I; Medical Oncology Department, IMIBIC, Reina Sofia University Hospital, University of Cordoba , Cordoba , Spain., Rodriguez-Ariza A; Medical Oncology Department, IMIBIC, Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Madrid, Spain., Moreno-Vega A; Medical Oncology Department, IMIBIC, Reina Sofia University Hospital, University of Cordoba , Cordoba , Spain., Ortiz-Morales MJ; Medical Oncology Department, IMIBIC, Reina Sofia University Hospital, University of Cordoba , Cordoba , Spain., Gomez-España MA; Medical Oncology Department, IMIBIC, Reina Sofia University Hospital, University of Cordoba , Cordoba , Spain., Cano-Osuna MT; Medical Oncology Department, IMIBIC, Reina Sofia University Hospital, University of Cordoba , Cordoba , Spain., Lopez-Gonzalez J; Medical Oncology Department, IMIBIC, Reina Sofia University Hospital, University of Cordoba , Cordoba , Spain., Chia-Delgado B; Medical Oncology Department, IMIBIC, Reina Sofia University Hospital, University of Cordoba , Cordoba , Spain., Gonzalez-Fernandez R; Immunology Department, IMIBIC, Reina Sofia University Hospital, University of Cordoba , Cordoba , Spain., Aranda-Aguilar E; Medical Oncology Department, IMIBIC, Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain; Spanish Cancer Network (RTICC), Instituto de Salud Carlos III, Madrid, Spain.
Publikováno v:
Frontiers in immunology [Front Immunol] 2016 Dec 05; Vol. 7, pp. 561. Date of Electronic Publication: 2016 Dec 05 (Print Publication: 2016).
Publikováno v:
Medicina clinica [Med Clin (Barc)] 2012 Apr 21; Vol. 138 (10), pp. 456-7. Date of Electronic Publication: 2011 Oct 05.
Autor:
Mazard, Thibault, Mollevi, Caroline, Loyer, Evelyne M., Léger, Julie, Chautard, Romain, Bouché, Olivier, Borg, Christophe, Armand-Dujardin, Paul, Bleuzen, Aurore, Assenat, Eric, Lecomte, Thierry
Publikováno v:
Cancer Imaging; 6/17/2024, Vol. 24 Issue 1, p1-12, 12p
Autor:
Zhang K; State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, 530021, Guangxi, China., Shi Y; State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, 530021, Guangxi, China., Jin Z; State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, 530021, Guangxi, China., He J; State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, 530021, Guangxi, China. hejian@gxmu.edu.cn.
Publikováno v:
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Sep; Vol. 26 (9), pp. 2084-2096. Date of Electronic Publication: 2024 Mar 20.
Autor:
Ferreira, Cláudia S., Babitzki, Galina, Klaman, Irina, Krieter, Oliver, Lechner, Katharina, Bendell, Johanna, Harring, Suzana Vega, Heil, Florian
Publikováno v:
Frontiers in Oncology; 2023, p1-13, 13p